Strides Shasun to launch Ranitidine (OTC) Tablets in US
Capital MarketStrides Shasun announced that it will launch Ranitidine Tablets USP, 150 mg (OTC) in the US markets. Strides is already a key player in the US Ranitidine Rx market with 32% market share through its approval for Ranitidine Tablets USP, 150 mg and 300 mg. The new launch will further strengthen company's Ranitidine franchise. According to IRI data, the US OTC market for Ranitidine Tablets, which is the generic form of the popular brand Zantac, is approximately USD 200 Million.
This is the first product approval from company's 50:50 JV with Vivimed Labs. The product will be backward integrated and will be manufactured at the JV's Oral dosage facility in Chennai. Strides will have exclusive marketing rights for the product in the US. The product will be launched immediately.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
